Τίτλος:
Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Azilsartan medoxomil (AZM) is the newest representative in the class of angiotensin receptor blockers. Azilsartan medoxomil in combination with the older diuretic chlorthalidone (CLD) in fixed-doses of AZM/CLD 40/12.5 mg and 40/25 mg has been approved by the FDA for use in patients with essential hypertension. We sought to evaluate the safety and tol-erability of AZL-M alone and in combination with CLD. Methods: We conducted a search in PubMed using the keywords ‘azilsartan’, ‘azilsartan medox-omil’, ‘chlorthalidone, ‘safety’, ‘tolerability’ in order to find scientific studies evaluating the safety of these drugs. We included studies reporting side effects of these drugs, alone or in combination, in comparison to placebo or other antihypertensive medications. For our systematic review, we followed the PRISMA guidelines. Results: Azilsartan medoxomil is a potent antihypertensive medicine with an acceptable safety pro-file. The most commonly reported adverse events are dizziness, headache, fatigue, upper respirato-ry tract infection and urinary tract infection. Chlorthalidone is more potent and has a considerably longer duration of action than the most commonly prescribed diuretic hydrochlorothiazide. Safety and tolerability between these two drugs are similar except higher serum uric acid and lower potas-sium levels with chlorthalidone. Conclusion: The combination of azilsartan medoxomil with chlorthalidone has been shown to be effective in lowering blood pressure with an acceptable safety and tolerability profile. This fixed-dose combination is an attractive treatment option for hypertension management. © 2021 Bentham Science Publishers.
Συγγραφείς:
Katsi, V.
Michalakeas, C.
Soulaidopoulos, S.
Antonopoulos, A.S.
Vlachopoulos, C.-A.
Tousoulis, D.
Tsioufis, K.
Περιοδικό:
Current Hypertension Reviews
Εκδότης:
Bentham Science Publishers
Λέξεις-κλειδιά:
antihypertensive agent; azilsartan medoxomil; calcium channel blocking agent; chlortalidone; dipeptidyl carboxypeptidase; diuretic agent; ramipril; angiotensin 1 receptor antagonist; antihypertensive agent; azilsartan medoxomil; benzimidazole derivative; chlortalidone; oxadiazole derivative; uric acid, asthenia; blood pressure; chronic kidney failure; creatinine blood level; diarrhea; dizziness; drug safety; drug tolerability; electrocardiogram; electrolyte disturbance; erythema; fatigue; follow up; headache; human; hyperglycemia; hypertension; hyperuricemia; hypokalemia; hyponatremia; meta analysis; muscle spasm; outcome assessment; quality control; randomized controlled trial (topic); Review; rhinopharyngitis; systematic review; upper respiratory tract infection; urinary tract infection; combination drug therapy; hypertension; treatment outcome, Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Humans; Hypertension; Oxadiazoles; Treatment Outcome; Uric Acid
DOI:
10.2174/1573402117666210112144505
